MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
countries have benefitted from access to MPP-licensed products
ongoing pharmaceutical development projects
Billion dollars saved by the international community, from January 2012 to June 2020
Billion doses of treatment supplied from January 2012 to June 2020
Million patient-years of treatment through MPP’s generic partners, from January 2012 to June 2020
KPMG calculated savings of USD 1.66 billion and supply of 38.75 million patient-years of treatments through MPP’s generic partners from January 2012 to June 2020. Read the KPMG report.
Impact analysis, highlighting MPP’s sublicensees’ progress on treatments development, are available here.